-
1
-
-
33644746018
-
Role of pharmacogenetics in irinotecan therapy
-
DOI 10.1016/j.canlet.2005.04.040, PII S0304383505009298, Pharmacogenomics in Cancer Chemotherapy: Recent Advances in Drug Transporters and Genome Analysis
-
FA de Jong MJA de Jonge J Verweij RHJ Mathijssen 2006 Role of pharmacogenetics in irinotecan therapy Cancer Lett 234 90 106 10.1016/j.canlet.2005.04.040 16343744 (Pubitemid 43343943)
-
(2006)
Cancer Letters
, vol.234
, Issue.1
, pp. 90-106
-
-
De Jong, F.A.1
De Jonge, M.J.A.2
Verweij, J.3
Mathijssen, R.H.J.4
-
2
-
-
33745928751
-
Management of advanced colorectal cancer: State of the art
-
DOI 10.1038/sj.bjc.6603233, PII 6603233
-
M Saunders T Iveson 2006 Management of advanced colorectal cancer: state of the art Br J Cancer 95 131 138 10.1038/sj.bjc.6603233 1:CAS:528: DC%2BD28XmvFajsL4%3D 16835584 (Pubitemid 44050911)
-
(2006)
British Journal of Cancer
, vol.95
, Issue.2
, pp. 131-138
-
-
Saunders, M.1
Iveson, T.2
-
3
-
-
33749249529
-
Irinotecan in the treatment of colorectal cancer
-
DOI 10.1016/j.ctrv.2006.07.001, PII S0305737206001368
-
C Fuchs EP Mitchell PM Hoff 2006 Irinotecan in the treatment of colorectal cancer Cancer Treat Rev 32 491 503 10.1016/j.ctrv.2006.07.001 1:CAS:528:DC%2BD28XhtVajsrfO 16959432 (Pubitemid 44478737)
-
(2006)
Cancer Treatment Reviews
, vol.32
, Issue.7
, pp. 491-503
-
-
Fuchs, C.1
Mitchell, E.P.2
Hoff, P.M.3
-
4
-
-
27644502351
-
Topotecan as second-line therapy for ovarian cancer: Dosage versus toxicity
-
DOI 10.1634/theoncologist.10-9-695
-
M Markman 2005 Topotecan as second-line therapy for ovarian cancer: dosage versus toxicity Oncologist 10 695 697 10.1634/theoncologist.10-9-695 1:CAS:528:DC%2BD2MXht1Cgs7fE 16249348 (Pubitemid 41567280)
-
(2005)
Oncologist
, vol.10
, Issue.9
, pp. 695-697
-
-
Markman, M.1
-
5
-
-
34347243879
-
Topotecan for the treatment of small-cell lung cancer
-
DOI 10.1586/14737140.7.6.795
-
SJ Nicum MER O'Brien 2007 Topotecan for the treatment of small-cell lung cancer Expert Rev Anticancer Ther 7 795 801 10.1586/14737140.7.6.795 1:CAS:528:DC%2BD2sXmtFOhtbo%3D 17555389 (Pubitemid 47007986)
-
(2007)
Expert Review of Anticancer Therapy
, vol.7
, Issue.6
, pp. 795-801
-
-
Nicum, S.J.1
O'Brien, M.E.R.2
-
7
-
-
0030958098
-
Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients
-
1:CAS:528:DyaK2sXivVehs7s%3D 9193346
-
E Gupta R Mick J Ramirez X Wang TM Lestingi EE Vokes MJ Ratain 1997 Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients J Clin Oncol 15 1502 1510 1:CAS:528: DyaK2sXivVehs7s%3D 9193346
-
(1997)
J Clin Oncol
, vol.15
, pp. 1502-1510
-
-
Gupta, E.1
Mick, R.2
Ramirez, J.3
Wang, X.4
Lestingi, T.M.5
Vokes, E.E.6
Ratain, M.J.7
-
8
-
-
3042677708
-
Flat-fixed dosing of irinotecan: Influence on pharmacokinetic and pharmacodynamic variability
-
DOI 10.1158/1078-0432.CCR-03-0591
-
FA de Jong RHJ Mathijssen R Xie J Verweij A Sparreboom 2004 Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability Clin Cancer Res 10 4068 4071 10.1158/1078-0432.CCR-03-0591 15217940 (Pubitemid 38812483)
-
(2004)
Clinical Cancer Research
, vol.10
, pp. 4068-4071
-
-
De Jong, F.A.1
Mathijssen, R.H.J.2
Xie, R.3
Verweij, J.4
Sparreboom, A.5
-
9
-
-
0032130703
-
Gastrointestinal toxicity or irinotecan
-
1:STN:280:DyaK1czpsVWmuw%3D%3D 9726096
-
JR Hecht 1998 Gastrointestinal toxicity or irinotecan Oncology 12 72 78 1:STN:280:DyaK1czpsVWmuw%3D%3D 9726096
-
(1998)
Oncology
, vol.12
, pp. 72-78
-
-
Hecht, J.R.1
-
10
-
-
0032731703
-
The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11)
-
1:CAS:528:DyaK1MXns1yhuro%3D 10570064
-
HM Dodds LP Rivory 1999 The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11) Mol Pharmacol 56 1346 1353 1:CAS:528:DyaK1MXns1yhuro%3D 10570064
-
(1999)
Mol Pharmacol
, vol.56
, pp. 1346-1353
-
-
Dodds, H.M.1
Rivory, L.P.2
-
11
-
-
0031661579
-
UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
-
DOI 10.1023/A:1008438109725
-
Y Ando H Saka G Asai S Sugiura K Shimokata T Kamataki 1998 UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan Ann Oncol 9 845 847 10.1023/A:1008438109725 1:STN:280:DyaK1M%2Fgs1Sgtw%3D%3D 9789606 (Pubitemid 28440442)
-
(1998)
Annals of Oncology
, vol.9
, Issue.8
, pp. 845-847
-
-
Ando, Y.1
Saka, H.2
Asai, G.3
Sugiura, S.4
Shimokata, K.5
Kamataki, T.6
-
12
-
-
0032934383
-
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
-
DOI 10.1016/S0009-9236(99)70078-0
-
L Iyer D Hall S Das MA Mortell J Ramírez S Kim AD Rienzo MJ Ratain 1999 Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism Clin Pharmacol Ther 65 576 582 10.1016/S0009-9236(99) 70078-0 1:CAS:528:DyaK1MXjslSrt74%3D 10340924 (Pubitemid 29237332)
-
(1999)
Clinical Pharmacology and Therapeutics
, vol.65
, Issue.5
, pp. 576-582
-
-
Iyer, L.1
Hall, D.2
Das, S.3
Mortell, M.A.4
Ramirez, J.5
Kim, S.6
Di Rienzo, A.7
Ratain, M.J.8
-
13
-
-
0036148810
-
Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan
-
DOI 10.1097/00007691-200202000-00018
-
Y Ando H Ueoka T Sugiyama M Ichiki K Shimokata Y Hasegawa 2002 Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan Ther Drug Monit 24 111 116 10.1097/00007691-200202000-00018 1:CAS:528: DC%2BD38XhsVOitLg%3D 11805731 (Pubitemid 34106739)
-
(2002)
Therapeutic Drug Monitoring
, vol.24
, Issue.1
, pp. 111-116
-
-
Ando, Y.1
Ueoka, H.2
Sugiyama, T.3
Ichiki, M.4
Shimokata, K.5
Hasegawa, Y.6
-
14
-
-
0036025450
-
UGT1A128 polymorphism as a determinant of irinotecan disposition and toxicity
-
DOI 10.1038/sj.tpj.6500072
-
L Iyer S Das L Janisch M Wen J Ramírez T Karrison GF Fleming EE Vokes RL Schilsky MJ Ratain 2002 UGT1A128 polymorphism as a determinant of irinotecan disposition and toxicity Pharmacogenomics J 2 43 47 10.1038/sj.tpj.6500072 1:CAS:528:DC%2BD38Xitl2ju7k%3D 11990381 (Pubitemid 34982202)
-
(2002)
Pharmacogenomics Journal
, vol.2
, Issue.1
, pp. 43-47
-
-
Iyer, L.1
Das, S.2
Janisch, L.3
Wen, M.4
Ramirez, J.5
Karrison, T.6
Fleming, G.F.7
Vokes, E.E.8
Schilsky, R.L.9
Ratain, M.J.10
-
15
-
-
2342459714
-
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
-
DOI 10.1200/JCO.2004.07.173
-
F Innocenti SD Undevia L Iyer PX Chen S Das M Kocherginsky T Karrison L Janisch J Ramírez CM Rudin EE Vokes MJ Ratain 2004 Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan J Clin Oncol 22 1382 1388 10.1200/JCO.2004.07.173 1:CAS:528:DC%2BD2cXpt1yjtbk%3D 15007088 (Pubitemid 41103619)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.8
, pp. 1382-1388
-
-
Innocenti, F.1
Undevia, S.D.2
Iyer, L.3
Chen, P.X.4
Das, S.5
Kocherginsky, M.6
Karrison, T.7
Janisch, L.8
Ramirez, J.9
Rudin, C.M.10
Vokes, E.E.11
Ratain, M.J.12
-
16
-
-
4344632633
-
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
-
1:CAS:528:DC%2BD2cXmsVCgtr0%3D 15280927
-
E Marcuello A Altés A Menoyo E del Rio M Gómez-Pardo M Baiget 2004 UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer Br J Cancer 91 678 682 1:CAS:528: DC%2BD2cXmsVCgtr0%3D 15280927
-
(2004)
Br J Cancer
, vol.91
, pp. 678-682
-
-
Marcuello, E.1
Altés, A.2
Menoyo, A.3
Del Rio, E.4
Gómez-Pardo, M.5
Baiget, M.6
-
17
-
-
0034901949
-
Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients
-
1:CAS:528:DC%2BD3MXktlemurY%3D 11350876
-
DFS Kehrer A Sparreboom J Verweij P de Bruijn CA Nierop J van de Schraaf EJ Ruijgrok MJA de Jonge 2001 Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients Clin Cancer Res 7 1136 1141 1:CAS:528:DC%2BD3MXktlemurY%3D 11350876
-
(2001)
Clin Cancer Res
, vol.7
, pp. 1136-1141
-
-
Kehrer, D.F.S.1
Sparreboom, A.2
Verweij, J.3
De Bruijn, P.4
Nierop, C.A.5
Van De Schraaf, J.6
Ruijgrok, E.J.7
De Jonge, M.J.A.8
-
18
-
-
0034508219
-
Transport of topoisomerase i inhibitors by the breast cancer resistance protein. Potential clinical implications
-
1:CAS:528:DC%2BD3MXntVCrsA%3D%3D 11193894
-
JHM Schellens M Maliepaard RJ Scheper GL Scheffer JW Jonker JW Smit JH Beijnen AH Schinkel 2000 Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications Ann NY Acad Sci 922 188 194 1:CAS:528:DC%2BD3MXntVCrsA%3D%3D 11193894
-
(2000)
Ann NY Acad Sci
, vol.922
, pp. 188-194
-
-
Schellens, J.H.M.1
Maliepaard, M.2
Scheper, R.J.3
Scheffer, G.L.4
Jonker, J.W.5
Smit, J.W.6
Beijnen, J.H.7
Schinkel, A.H.8
-
19
-
-
0035834595
-
Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells
-
DOI 10.1006/bbrc.2001.5850
-
K Nakatomi M Yoshikawa M Oka Y Ikegami S Hayasaka K Sano K Shiozawa S Kawabata H Soda T Ishikawa S Tanabe S Kohno 2001 Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells Biochem Biophys Res Commun 288 827 832 10.1006/bbrc.2001.5850 1:CAS:528:DC%2BD3MXnvFGisLg%3D 11688982 (Pubitemid 33140956)
-
(2001)
Biochemical and Biophysical Research Communications
, vol.288
, Issue.4
, pp. 827-832
-
-
Nakatomi, K.1
Yoshikawa, M.2
Oka, M.3
Ikegami, Y.4
Hayasaka, S.5
Sano, K.6
Shiozawa, K.7
Kawabata, S.8
Soda, H.9
Ishikawa, T.10
Tanabe, S.11
Kohno, S.12
-
20
-
-
33750552551
-
Mechanisms of cellular resistance to camptothecins
-
DOI 10.2174/092986706778773121
-
GL Beretta P Perego F Zunino 2006 Mechanisms of cellular resistance to camptothecins Curr Med Chem 13 3291 3305 10.2174/092986706778773121 1:CAS:528:DC%2BD28XhtFyrtr%2FF 17168852 (Pubitemid 44669776)
-
(2006)
Current Medicinal Chemistry
, vol.13
, Issue.27
, pp. 3291-3305
-
-
Beretta, G.L.1
Perego, P.2
Zunino, F.3
-
21
-
-
0034666736
-
BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells
-
DOI 10.1016/S0006-2952(00)00396-8, PII S0006295200003968
-
CH Yang E Schneider ML Kuo EL Volk E Rocchi YC Chen 2000 BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells Biochem Pharmacol 60 831 837 10.1016/S0006-2952(00)00396-8 1:CAS:528:DC%2BD3cXltlWgtL4%3D 10930538 (Pubitemid 30621668)
-
(2000)
Biochemical Pharmacology
, vol.60
, Issue.6
, pp. 831-837
-
-
Yang, C.-H.1
Schneider, E.2
Kuo, M.-L.3
Volk, E.L.4
Rocchi, E.5
Chen, Y.-C.6
-
22
-
-
0034789387
-
Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells
-
DOI 10.1006/bbrc.2001.5130
-
C Özvegy T Litman G Szakács Z Nagy S Bates A Váradi B Sarkadi 2001 Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells Biochem Biophys Res Commun 285 111 117 10.1006/bbrc.2001.5130 11437380 (Pubitemid 32912517)
-
(2001)
Biochemical and Biophysical Research Communications
, vol.285
, Issue.1
, pp. 111-117
-
-
Ozvegy, C.1
Litman, T.2
Szakacs, G.3
Nagy, Z.4
Bates, S.5
Varadi, A.6
Sarkadi, B.7
-
23
-
-
0037050736
-
Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization
-
DOI 10.1002/ijc.10100
-
K Kage S Tsukahara T Sugiyama S Asada E Ishikawa T Tsuruo Y Sugimoto 2002 Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization Int J Cancer 97 626 630 10.1002/ijc.10100 1:CAS:528:DC%2BD38XpsFWjtA%3D%3D 11807788 (Pubitemid 34087801)
-
(2002)
International Journal of Cancer
, vol.97
, Issue.5
, pp. 626-630
-
-
Kage, K.1
Tsukahara, S.2
Sugiyama, T.3
Asada, S.4
Ishikawa, E.5
Tsuruo, T.6
Sugimoto, Y.7
-
24
-
-
0036772386
-
Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material
-
DOI 10.1002/path.1203
-
JE Diestra GL Scheffer I Català M Maliepaard JHM Schellens RJ Scheper JR Germà-Lluch MA Izquierdo 2002 Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material J Pathol 198 213 219 10.1002/path.1203 1:CAS:528:DC%2BD3sXivV2jsrY%3D 12237881 (Pubitemid 35243879)
-
(2002)
Journal of Pathology
, vol.198
, Issue.2
, pp. 213-219
-
-
Diestra, J.E.1
Scheffer, G.L.2
Catala, I.3
Maliepaard, M.4
Schellens, J.H.M.5
Scheper, R.J.6
Germa-Lluch, J.R.7
Izquierdo, M.A.8
-
25
-
-
65349179115
-
Synthesis and biological activities of a pH-dependently activated water-soluble prodrug of a novel hexacyclic camptothecin analog
-
10.1016/j.bmcl.2009.03.123 1:CAS:528:DC%2BD1MXltl2rsLg%3D 19362835
-
J Ohwada S Ozawa M Kohchi H Fukuda C Murasaki H Suda T Murata S Niizuma M Tsukazaki K Ori K Yoshinari Y Itezono M Endo M Ura H Tanimura Y Miyazaki A Kawashima S Nagao E Namba K Ogawa K Kobayashi H Okabe I Umeda N Shimma 2009 Synthesis and biological activities of a pH-dependently activated water-soluble prodrug of a novel hexacyclic camptothecin analog Bioorg Med Chem Lett 19 2772 2776 10.1016/j.bmcl.2009.03.123 1:CAS:528:DC%2BD1MXltl2rsLg%3D 19362835
-
(2009)
Bioorg Med Chem Lett
, vol.19
, pp. 2772-2776
-
-
Ohwada, J.1
Ozawa, S.2
Kohchi, M.3
Fukuda, H.4
Murasaki, C.5
Suda, H.6
Murata, T.7
Niizuma, S.8
Tsukazaki, M.9
Ori, K.10
Yoshinari, K.11
Itezono, Y.12
Endo, M.13
Ura, M.14
Tanimura, H.15
Miyazaki, Y.16
Kawashima, A.17
Nagao, S.18
Namba, E.19
Ogawa, K.20
Kobayashi, K.21
Okabe, H.22
Umeda, I.23
Shimma, N.24
more..
-
26
-
-
39749119942
-
Next generation topoisomerase I inhibitors: Rationale and biomarker strategies
-
DOI 10.1016/j.bcp.2007.10.016, PII S0006295207006946
-
BA Teicher 2008 Next generation topoisomerase I inhibitors: rationale and biomarker strategies Biochem Pharmacol 75 1262 1271 10.1016/j.bcp.2007.10.016 1:CAS:528:DC%2BD1cXislamtL8%3D 18061144 (Pubitemid 351305209)
-
(2008)
Biochemical Pharmacology
, vol.75
, Issue.6
, pp. 1262-1271
-
-
Teicher, B.A.1
-
27
-
-
6344237103
-
ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases
-
DOI 10.1002/ijc.20032
-
L Candeil I Gourdier D Peyron N Vezzio V Copois F Bibeau B Orsetti GL Scheffer M Ychou QA Khan Y Pommier B Pau P Martineau M Del Rio 2004 ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases Int J Cancer 109 848 854 10.1002/ijc.20032 1:CAS:528: DC%2BD2cXjt1ensrc%3D 15027118 (Pubitemid 38500741)
-
(2004)
International Journal of Cancer
, vol.109
, Issue.6
, pp. 848-854
-
-
Candeil, L.1
Gourdier, I.2
Peyron, D.3
Vezzio, N.4
Copois, V.5
Bibeau, F.6
Orsetti, B.7
Scheffer, G.L.8
Ychou, M.9
Khan, Q.A.10
Pommier, Y.11
Pau, B.12
Martineau, P.13
Del Rio, M.14
-
28
-
-
0036163796
-
ABC Transporters as phenotypic markers and functional regulators of stem cells
-
10.1634/stemcells.20-3-274 1:CAS:528:DC%2BD38XhtlGktbs%3D 11796918
-
KD Bunting 2002 ABC Transporters as phenotypic markers and functional regulators of stem cells Stem Cells 20 11 20 10.1634/stemcells.20-3-274 1:CAS:528:DC%2BD38XhtlGktbs%3D 11796918
-
(2002)
Stem Cells
, vol.20
, pp. 11-20
-
-
Bunting, K.D.1
|